{
  "docId": "019de071-473e-712d-87f0-b99471a2308d",
  "docSlug": "b8bc6e04b9c70160cc1bc532a2ac4eea",
  "documentTitle": "Nuvalent | IPO Presentation Deck | 40 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7827299,
  "pageNumber": 29,
  "pageCount": 40,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 18,
  "notes": "The slide uses a color-coded heatmap to indicate potency (green for high potency, yellow for lower).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-473e-712d-87f0-b99471a2308d/29",
  "deckHref": "/decks/019de071-473e-712d-87f0-b99471a2308d",
  "deckJsonHref": "/decks/019de071-473e-712d-87f0-b99471a2308d.json",
  "deckAnchorHref": "/decks/019de071-473e-712d-87f0-b99471a2308d#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.18,
        "x": 0.02,
        "y": 0.25
      },
      "kind": "other",
      "text": "NVL-655 ALK-selective Target Product Profile sidebar",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0495bbf-43c1-4dd8-8327-e9ad6869104b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.225,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Wild-type ALK Fusions, in vitro NSCLC models",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0526db98-b938-49ea-8f8c-646b6247844e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.225,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Experiments not powered to determine the statistical significance of differences in measurements between any of the inhibitors tested. No head-to-head clinical studies have been conducted for currently approved therapies versus NVL-655. No clinical studies have been conducted with NVL-655. Pelish, H.E., Tangpeerachaikul, A., Kohl, N.E., Shair, M.D., Porter, J.R., and Horan, J.C. AACR Conference 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38082d58-bba4-44d9-a21d-6b84afb7249f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.75,
        "x": 0.225,
        "y": 0.4
      },
      "kind": "table",
      "text": "IC50 cell viability assay (nM) for NVL-655, Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib across NCI-H2228, NCI-H3122, and Ba/F3 EML4-ALK v1 cell lines.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22324eb5-5bcb-4c58-9a8b-81a4f5573561",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.225,
        "y": 0.105
      },
      "kind": "title",
      "text": "Preclinical NVL-655 activity against ALK",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c554a4e7-160c-439d-89b4-ffe2e3b622ca",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}